BIOTE CORP -A (BTMD) Stock Fundamental Analysis
NASDAQ:BTMD - Nasdaq - US0906831039 - Common Stock - Currency: USD
We assign a fundamental rating of 6 out of 10 to BTMD. BTMD was compared to 192 industry peers in the Pharmaceuticals industry. BTMD has only an average score on both its financial health and profitability. BTMD is evaluated to be cheap and growing strongly. This does not happen too often! These ratings could make BTMD a good candidate for value and growth investing.
1. Profitability
1.1 Basic Checks
BTMD had positive earnings in the past year.
BTMD had a positive operating cash flow in the past year.
BTMD had positive earnings in 4 of the past 5 years.
Of the past 5 years BTMD 4 years had a positive operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of 5.05%, BTMD belongs to the top of the industry, outperforming 89.06% of the companies in the same industry.
The Return On Invested Capital of BTMD (62.55%) is better than 99.48% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.05% | ||
| ROE | N/A | ||
| ROIC | 62.55% |
ROA(3y)20.43%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Profit Margin, with a value of 2.13%, BTMD belongs to the top of the industry, outperforming 83.85% of the companies in the same industry.
In the last couple of years the Profit Margin of BTMD has declined.
The Operating Margin of BTMD (18.67%) is better than 85.42% of its industry peers.
In the last couple of years the Operating Margin of BTMD has declined.
The Gross Margin of BTMD (70.32%) is better than 76.04% of its industry peers.
BTMD's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 18.67% | ||
| PM (TTM) | 2.13% | ||
| GM | 70.32% |
OM growth 3Y-17.24%
OM growth 5YN/A
PM growth 3Y-58.51%
PM growth 5YN/A
GM growth 3Y3.85%
GM growth 5YN/A
2. Health
2.1 Basic Checks
BTMD has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
The number of shares outstanding for BTMD has been increased compared to 1 year ago.
BTMD has a better debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 2.98 indicates that BTMD is not a great score, but indicates only limited risk for bankruptcy at the moment.
BTMD has a Altman-Z score of 2.98. This is in the better half of the industry: BTMD outperforms 73.44% of its industry peers.
BTMD has a debt to FCF ratio of 5.66. This is a neutral value as BTMD would need 5.66 years to pay back of all of its debts.
BTMD has a better Debt to FCF ratio (5.66) than 85.42% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 5.66 | ||
| Altman-Z | 2.98 |
ROIC/WACC6.43
WACC9.73%
2.3 Liquidity
BTMD has a Current Ratio of 1.50. This is a normal value and indicates that BTMD is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.50, BTMD is doing worse than 70.83% of the companies in the same industry.
BTMD has a Quick Ratio of 1.16. This is a normal value and indicates that BTMD is financially healthy and should not expect problems in meeting its short term obligations.
BTMD has a Quick ratio of 1.16. This is in the lower half of the industry: BTMD underperforms 72.92% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.5 | ||
| Quick Ratio | 1.16 |
3. Growth
3.1 Past
BTMD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 236.36%, which is quite impressive.
BTMD shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -66.72% yearly.
BTMD shows a strong growth in Revenue. In the last year, the Revenue has grown by 30.25%.
BTMD shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 16.71% yearly.
EPS 1Y (TTM)236.36%
EPS 3Y-66.72%
EPS 5YN/A
EPS Q2Q%37.5%
Revenue 1Y (TTM)30.25%
Revenue growth 3Y16.71%
Revenue growth 5YN/A
Sales Q2Q%12.79%
3.2 Future
The Earnings Per Share is expected to grow by 62.73% on average over the next years. This is a very strong growth
BTMD is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 16.03% yearly.
EPS Next Y174.18%
EPS Next 2Y115.2%
EPS Next 3Y75.78%
EPS Next 5Y62.73%
Revenue Next Year7.02%
Revenue Next 2Y10.68%
Revenue Next 3Y12.37%
Revenue Next 5Y16.03%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 14.20 indicates a correct valuation of BTMD.
Based on the Price/Earnings ratio, BTMD is valued cheaper than 89.06% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 29.35. BTMD is valued rather cheaply when compared to this.
Based on the Price/Forward Earnings ratio of 7.36, the valuation of BTMD can be described as very cheap.
BTMD's Price/Forward Earnings ratio is rather cheap when compared to the industry. BTMD is cheaper than 92.71% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.10, BTMD is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 14.2 | ||
| Fwd PE | 7.36 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, BTMD is valued cheaply inside the industry as 88.02% of the companies are valued more expensively.
Based on the Price/Free Cash Flow ratio, BTMD is valued cheaply inside the industry as 94.27% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 7.03 | ||
| EV/EBITDA | 7.8 |
4.3 Compensation for Growth
BTMD's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
BTMD has a very decent profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as BTMD's earnings are expected to grow with 75.78% in the coming years.
PEG (NY)0.08
PEG (5Y)N/A
EPS Next 2Y115.2%
EPS Next 3Y75.78%
5. Dividend
5.1 Amount
BTMD does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
4.26
+0.05 (+1.19%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners67.42%
Inst Owner Change4.63%
Ins Owners27.6%
Ins Owner Change0%
Market Cap231.49M
Analysts83.33
Price Target10.15 (138.26%)
Short Float %2.88%
Short Ratio5.1
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-5.1%
Min EPS beat(2)-269.68%
Max EPS beat(2)259.48%
EPS beat(4)2
Avg EPS beat(4)-39.13%
Min EPS beat(4)-276.49%
Max EPS beat(4)259.48%
EPS beat(8)4
Avg EPS beat(8)-99.95%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-1.85%
Min Revenue beat(2)-1.96%
Max Revenue beat(2)-1.75%
Revenue beat(4)1
Avg Revenue beat(4)-1.34%
Min Revenue beat(4)-2.04%
Max Revenue beat(4)0.38%
Revenue beat(8)3
Avg Revenue beat(8)-1%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)4.31%
EPS NQ rev (1m)0%
EPS NQ rev (3m)7.15%
EPS NY rev (1m)0%
EPS NY rev (3m)14.29%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.1%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.05%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 14.2 | ||
| Fwd PE | 7.36 | ||
| P/S | 0.97 | ||
| P/FCF | 7.03 | ||
| P/OCF | 5.81 | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | 7.8 |
EPS(TTM)0.3
EY7.04%
EPS(NY)0.58
Fwd EY13.59%
FCF(TTM)0.61
FCFY14.23%
OCF(TTM)0.73
OCFY17.21%
SpS4.41
BVpS-2.4
TBVpS-2.7
PEG (NY)0.08
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.05% | ||
| ROE | N/A | ||
| ROCE | 81.8% | ||
| ROIC | 62.55% | ||
| ROICexc | 207.32% | ||
| ROICexgc | 9485.53% | ||
| OM | 18.67% | ||
| PM (TTM) | 2.13% | ||
| GM | 70.32% | ||
| FCFM | 13.74% |
ROA(3y)20.43%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y-70.62%
ROICexcg growth 5YN/A
ROICexc growth 3Y-57.71%
ROICexc growth 5YN/A
OM growth 3Y-17.24%
OM growth 5YN/A
PM growth 3Y-58.51%
PM growth 5YN/A
GM growth 3Y3.85%
GM growth 5YN/A
F-Score7
Asset Turnover2.37
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 5.66 | ||
| Debt/EBITDA | 3.2 | ||
| Cap/Depr | 174.15% | ||
| Cap/Sales | 2.87% | ||
| Interest Coverage | 4.58 | ||
| Cash Conversion | 81.73% | ||
| Profit Quality | 643.79% | ||
| Current Ratio | 1.5 | ||
| Quick Ratio | 1.16 | ||
| Altman-Z | 2.98 |
F-Score7
WACC9.73%
ROIC/WACC6.43
Cap/Depr(3y)148.8%
Cap/Depr(5y)153.91%
Cap/Sales(3y)1.77%
Cap/Sales(5y)1.6%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)236.36%
EPS 3Y-66.72%
EPS 5YN/A
EPS Q2Q%37.5%
EPS Next Y174.18%
EPS Next 2Y115.2%
EPS Next 3Y75.78%
EPS Next 5Y62.73%
Revenue 1Y (TTM)30.25%
Revenue growth 3Y16.71%
Revenue growth 5YN/A
Sales Q2Q%12.79%
Revenue Next Year7.02%
Revenue Next 2Y10.68%
Revenue Next 3Y12.37%
Revenue Next 5Y16.03%
EBIT growth 1Y47.06%
EBIT growth 3Y-3.41%
EBIT growth 5YN/A
EBIT Next Year89.15%
EBIT Next 3Y37.36%
EBIT Next 5Y30.22%
FCF growth 1Y527.35%
FCF growth 3Y-1.17%
FCF growth 5YN/A
OCF growth 1Y876.37%
OCF growth 3Y0.57%
OCF growth 5YN/A